ImmunoGenesis
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2450 Holcombe Blvd Ste J, Houston, Texas...Phone Number
(346) 772-0336Website
www.immunogenesis.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ImmunoGenesis
ImmunoGenesis is focused on developing next-generation immunotherapies aimed at treating 'cold' cancers that are resistant to current immunotherapy options. Their lead molecule, IMGS-001, is designed to dismantle barriers preventing T cells from attacking tumors, while additional products like IMGS-101 and IMGS-203 target specific challenges in the tumor microenvironment. The company aims to redefine treatable cancers and expand the population benefiting from immunotherapy, addressing a significant unmet need in the oncology market. With ongoing clinical trials and a commitment to innovative drug design, ImmunoGenesis is positioned to lead the next wave of immunotherapy advancements.Explore more
ImmunoGenesis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ImmunoGenesis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at ImmunoGenesis
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once ImmunoGenesis has new funding data
ImmunoGenesis, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ImmunoGenesis is spiking on competitors!
Product Launch: Get notified when ImmunoGenesis launches new products
Earning: See what the market has to say on ImmunoGenesis recently announced quarterly report
Check if ImmunoGenesis has recently received funding, and reach out quickly before it becomes old news!
Click to see if ImmunoGenesis had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to ImmunoGenesis
Compare insights from companies similar to ImmunoGenesis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ImmunoGenesis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ImmunoGenesis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ImmunoGenesis.
ImmunoGenesis Tech Stack
A closer look at the technologies used by ImmunoGenesis
See more technologies
ImmunoGenesis News & Media
ImmunoGenesis Announces the Formation of Scientific Advisory Board
Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many "immune-excluded" cancers that are resistant to existing...ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON, May 30, 2025 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing...ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center
The Phase 1 trial of IMGS-001-a novel dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function-is expanding to Ochsner MD Anderson Cancer Center.ImmunoGenesis to Present in Innovation Track of the 2025 NeauxCancer Oncology Conference in New Orleans
Conference Innovation Track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology HOUSTON, March 20, 2025 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announces its...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ImmunoGenesis
Sign Up For FreeTo access detailed company insights
ImmunoGenesis is focused on developing next-generation immunotherapies aimed at treating 'cold' cancers that are resistant to current immunotherapy options. Their lead molecule, IMGS-001, is designed to dismantle barriers preventing T cells from attacking tumors, while additional products like IMGS-101 and IMGS-203 target specific challenges in the... Read More
